Loss of Antidepressant Efficacy During Maintenance Therapy: Possible Mechanisms and Treatments
The DOI matches its Crossref record.
Abstract
BACKGROUND: Many patients with unipolar depression experience a return of depressive symptoms while taking a constant maintenance dose of an antidepressant. METHOD: All cited studies were found using computerized literature searches of the MEDLINE database since 1966. RESULTS: The return of depressive symptoms during maintenance antidepressant treatment has occurred in 9% to 57% of patients in published trials. Possible explanations include loss of placebo effect, pharmacologic tolerance, increase in disease severity, change in disease pathogenesis, the accumulation of a detrimental metabolite, unrecognized rapid cycling, and prophylactic inefficacy. CONCLUSION: Although several strategies have been proposed to overcome the loss of antidepressant efficacy, double-blind controlled studies are needed to ascertain the optimal strategy for this perplexing clinical problem.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“with the return of depressive symptoms of MDD occurring in 9-33% of patients across published trials [3].”
In the citing paper
“For instance, it was postulated that the activation of processes driving tolerance to antidepressant drugs may occur to at varying degrees in every patient receiving antidepressants [3], may only manifest themselves and then be recognized in patients with chronic and recurrent forms of depression who had previously responded to antidepressant therapy at some time [37].”
Citations
Cites
Still being checked.
Cited by
Anderson, I., Ferrier, I., Baldwin, R., Cowen, P., Howard, L., Lewis, G., Matthews, K., McAllister-Williams, R., Peveler, R., Scott, J., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107088441 · Cited by 908
Malhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842
“Even with ongoing maintenance treatment recurrences can occur (Byrne and Rothschild, 1998).”
BackgroundCleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
Sex differences in depression: Insights from clinical and preclinical studies
Eid, R. S., Gobinath, A. R., & Galea, L. A. M. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.01.006 · Cited by 457
Treatment selection in depression.
Cohen, Z. D., & DeRubeis, R. J. (2018) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050817-084746 · Cited by 435
“Prior exposure to ADMs and history of nonresponse to ADMs have each been found consistently to predict poor response to future courses of antidepressants (Amsterdam et al. 2009, 2016; Amsterdam & Shults 2009; Byrne & Rothschild 1998).”
BackgroundBenmansour, S., Cecchi, M., Morilak, D. A., Gerhardt, G. A., Javors, M. A., Gould, G. G., & Frazer, A. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-23-10494.1999 · Cited by 337
Vagus nerve stimulation (VNS) for major depressive episodes: one year outcomes
Marangell, L. B., Rush, A. J., George, M. S., Sackeim, H. A., Johnson, C. R., Husain, M. M., Nahas, Z., & Lisanby, S. H. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01343-9 · Cited by 290
Andrews, P. W., Bharwani, A., Lee, K. R., Fox, M., & Thomson, J. A. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.01.018 · Cited by 281
Uebelacker, L. A., Epstein-Lubow, G., Gaudiano, B. A., Tremont, G., Battle, C. L., & Miller, I. W. (2010) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000367775.88388.96 · Cited by 280
The role of the brain reward system in depression
Naranjo, C. A., Tremblay, L. K., & Busto, U. E. (2001) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00156-7 · Cited by 245
Can long-term treatment with antidepressant drugs worsen the course of depression?
Fava, G. A. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0204 · Cited by 223
Daws, L. C. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.10.004 · Cited by 223
Greenhalgh, J., Knight, C., Hind, D., Beverley, C., & Walters, S. (2005) · Health Technology Assessment · doi:10.3310/hta9090 · Cited by 197
Wainwright, S. R., & Galea, L. A. M. (2013) · Neural Plasticity · doi:10.1155/2013/805497 · Cited by 162
“Even in patients that are initially responsive to treatment, up to 57% will have depressive symptoms return due to a loss of drug efficacy [40].”
The mechanisms of tolerance in antidepressant action
Fava, G. A., & Offidani, E. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.07.026 · Cited by 158
“Possible explanations include pharmacological tolerance, loss of placebo effect, increase in disease severity, change in disease pathogenesis, the accumulation of a detrimental metabolite, unrecognized rapid cycling, and prophylactic inefficacy (Byrne and Rothschild, 1998).”
Clinical issues in long-term treatment with antidepressants.
Zajecka, J. M. (2000) · PubMed · Cited by 144
Understanding pain in depression
Stahl, S., & Briley, M. (2004) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.619 · Cited by 126
An adaptationist perspective on the etiology of depression
Durisko, Z., Mulsant, B. H., & Andrews, P. W. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.09.032 · Cited by 140
Terapia cognitivo-comportamental da depressão
Powell, V. B., Abreu, N., Oliveira, I. R. D., & Sudak, D. (2008) · Revista Brasileira de Psiquiatria · doi:10.1590/s1516-44462008000600004 · Cited by 45
Residual symptoms in depression
Fava, G. A., Fabbri, S., & Sonino, N. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(02)00226-9 · Cited by 137
Lithium specificity in bipolar illness: a classic agent for the classic disorder
Gershon, S., Chengappa, K. R., & Malhi, G. S. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00709.x · Cited by 116
Primum Non Nocere: An Evolutionary Analysis of Whether Antidepressants Do More Harm than Good
Andrews, P. W., Thomson, J. A., Amstadter, A., & Neale, M. C. (2012) · Frontiers in Psychology · doi:10.3389/fpsyg.2012.00117 · Cited by 120
Uebelacker, L. A., Tremont, G., Epstein-Lubow, G., Gaudiano, B. A., Gillette, T., Kalibatseva, Z., & Miller, I. W. (2010) · Behavior Modification · doi:10.1177/0145445510368845 · Cited by 89
Predictors of Relapse in a Prospective Study of Fluoxetine Treatment of Major Depression
McGrath, P. J., Stewart, J. W., Quitkin, F. M., Chen, Y., Alpert, J. E., Nierenberg, A. A., Fava, M., Cheng, J., & Petkova, E. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.9.1542 · Cited by 111
Andrews, P. W., Kornstein, S. G., Halberstadt, L. J., Gardner, C. O., & Neale, M. C. (2011) · Frontiers in Psychology · doi:10.3389/fpsyg.2011.00159 · Cited by 107
“It is not uncommon for depressive symptoms to reemerge after remission while patients are on maintenance ADM therapy (Byrne and Rothschild, 1998), which is www.frontiersin.org July 2011 | Volume 2 | Article 159 | 3 sion, the ventrolateral prefrontal cortex (VLPFC) is thought to be important…”
Clinical practice recommendations for depression
Malhi, G. S., Adams, D., Porter, R., Wignall, A., Lampe, L., O’Connor, N., Paton, M., Newton, L. A., Walter, G., Taylor, A., et al. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01382.x · Cited by 96
Is unrecognized bipolar disorder a frequent contributor to apparent treatment resistant depression?
Correa, R., Akiskal, H. S., Gilmer, W. S., Nierenberg, A. A., Trivedi, M. H., & Zisook, S. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.06.036 · Cited by 101
Rational Use of Antidepressant Drugs
Fava, G. A. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000362803 · Cited by 95
Preventing Relapse and Recurrence of Depression:A Brief Review of Therapeutic Options
Thase, M. E. (2006) · CNS Spectrums · doi:10.1017/s1092852900015212 · Cited by 93
“"(17) Regardless of the name, putative causes of the apparent failure of maintenance pharmacotherapy include nonadherence, development of pharmacodynamic tolerance, increase in disease severity or change in disease pathogenesis, depleted effector substance, serum drug levels that have drifted below or above that drug'…”
BackgroundResultInfluentialFava, G. A., Ruini, C., Rafanelli, C., & Grandi, S. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.12.2094 · Cited by 88
Gobinath, A. R., Choleris, E., & Galea, L. A. M. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.23872 · Cited by 87
Leykin, Y., Amsterdam, J. D., DeRubeis, R. J., Gallop, R., Shelton, R. C., & Hollon, S. D. (2007) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.75.2.267 · Cited by 82
Tardive dysphoria: The role of long term antidepressant use in-inducing chronic depression
El‐Mallakh, R. S., Gao, Y., & Roberts, R. J. (2011) · Medical Hypotheses · doi:10.1016/j.mehy.2011.01.020 · Cited by 81
Fornaro, M., Anastasia, A., Novello, S., Fusco, A., Pariano, R., De Berardis, D., Solmi, M., Veronese, N., Stubbs, B., Vieta, E., et al. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2018.10.025 · Cited by 80
The Intellectual Crisis of Psychiatric Research
Fava, G. A. (2006) · Psychotherapy and Psychosomatics · doi:10.1159/000092890 · Cited by 79
Increased Recognition of Depression in Primary Care
Berardi, D., Menchetti, M., Cevenini, N., Scaini, S., Versari, M., & de Ronchi, D. (2005) · Psychotherapy and Psychosomatics · doi:10.1159/000085146 · Cited by 71
Long-Term Treatment with Antidepressant Drugs: The Spectacular Achievements of Propaganda
Fava, G. A. (2002) · Psychotherapy and Psychosomatics · doi:10.1159/000056279 · Cited by 66
Treatment of Recurrent Depression: A Sequential Psychotherapeutic and Psychopharmacological Approach
Fava, G. A., Ruini, C., & Sonino, N. (2003) · CNS Drugs · doi:10.2165/00023210-200317150-00005 · Cited by 70
Antidepressants: A triumph of marketing over science?
Antonuccio, D. O., Burns, D. D., & Danton, W. G. (2002) · Prevention & Treatment · doi:10.1037/1522-3736.5.1.525c · Cited by 62
Treatment Approaches to Major Depressive Disorder Relapse
Schmidt, M. E., Fava, M., Zhang, S., Gonzales, J., Raute, N. J., & Judge, R. (2002) · Psychotherapy and Psychosomatics · doi:10.1159/000063643 · Cited by 60
Duclot, F., Hollis, F., Darcy, M. J., & Kabbaj, M. (2011) · Physiology & Behavior · doi:10.1016/j.physbeh.2010.12.014 · Cited by 49
Zorumski, C. F., Nagele, P., Mennerick, S., & Conway, C. R. (2015) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2015.00172 · Cited by 57
Antidepressant-associated chronic irritable dysphoria (acid) in bipolar disorder: a case series
EI‐Mallakh, R. S., & Karippot, A. (2004) · Journal of Affective Disorders · doi:10.1016/j.jad.2004.08.004 · Cited by 57
Pharmacotherapy to sustain the fully remitted state
Kennedy, S., McIntyre, R., Fallu, A., & Lam, R. (2002) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0245 · Cited by 56
“This relapse or recurrence of depression while on antidepressant maintenance therapy has been experienced by patients treated with monoamine oxidase inhibitors, tricyclics and SSRIs; it is reported to occur in 9%–57% of patients.(56) Proposed causes of this real or apparent tolerance include pharmacological tolerance,…”
Stahl, S. M. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0401 · Cited by 44
Kulmatycki, K. M., & Jamali, F. (2006) · PubMed · Cited by 55
Sharma, V. (2001) · Journal of Affective Disorders · doi:10.1016/s0165-0327(00)00212-3 · Cited by 54
Voluntary running influences the efficacy of fluoxetine in a model of postpartum depression
Gobinath, A. R., Richardson, R. J., Chow, C., Workman, J. L., Lieblich, S. E., Barr, A. M., & Galea, L. A. M. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.09.017 · Cited by 54
Psychopharmacologic Treatments for Nonparaphilic Compulsive Sexual Behaviors
Kafka, M. (2000) · CNS Spectrums · doi:10.1017/s1092852900012669 · Cited by 50
Nierenberg, A. A., Quitkin, F. M., Kremer, C., Keller, M. B., & Thase, M. E. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300405 · Cited by 51
“An enigma associated with virtually all antidepressants is inexplicable relapse during continuation or maintenance treatment (Byrne and Rothschild, 1998; Nierenberg and Alpert, 2000), a phenomenon referred to as tachyphylaxis.”
BackgroundMaintenance Treatment of Insomnia: What Can We Learn From the Depression Literature?
Jindal, R. D., Buysse, D. J., & Thase, M. E. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.19 · Cited by 43
Skärsäter, I., Dencker, K., Bergbom, I., Häggström, L., & Fridlund, B. (2003) · Issues in Mental Health Nursing · doi:10.1080/01612840305313 · Cited by 46
Tachyphylaxis in major depressive disorder: A review of the current state of research
Kinrys, G., Gold, A. K., Pisano, V. D., Freeman, M. P., Papakostas, G. I., Mischoulon, D., Nierenberg, A. A., & Fava, M. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.10.357 · Cited by 45
The Neglected Role of Psychotherapy for Treatment-Resistant Depression
Markowitz, J. C., Wright, J. H., Peeters, F., Thase, M. E., Kocsis, J. H., & Sudak, D. M. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2021.21050535 · Cited by 41
The Missing Link between Clinical States and Biomarkers in Mental Disorders
Fava, G. A., Guidi, J., Grandi, S., & Hasler, G. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000360348 · Cited by 35
Treatment-Resistant Depression: New Therapies on the Horizon
Trivedi, M. H. (2003) · Annals of Clinical Psychiatry · doi:10.3109/10401230309085670 · Cited by 39
Relief of SSRI-Induced Sexual Dysfunction With Mirtazapine Treatment
Farah, A. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0412a · Cited by 39
Clinical judgment in psychiatry. Requiem or reveille?
Fava, G. A. (2013) · Nordic Journal of Psychiatry · doi:10.3109/08039488.2012.701665 · Cited by 38
Standard and Innovative Strategies in Cognitive Behavior Therapy
de Oliveira, I. R. (2012) · InTech eBooks · doi:10.5772/1161 · Cited by 37
Johnson, C. F. A., Maxwell, M., Williams, B., Dougall, N. J., & MacGillivray, S. A. (2022) · BMJ Medicine · doi:10.1136/bmjmed-2021-000017 · Cited by 35
Kaplan, E. M. (2002) · Clinical Therapeutics · doi:10.1016/s0149-2918(02)80029-7 · Cited by 34
Obsessive-Compulsive Symptoms With Risperidone
Mahendran, R. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0412b · Cited by 31
A stubborn behaviour: The failure of antidepressants to reduce suicide rates
van Praag, H. M. (2003) · The World Journal of Biological Psychiatry · doi:10.1080/15622970310029917 · Cited by 30
Cosci, F., Mansueto, G., & Fava, G. A. (2020) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2020.1779308 · Cited by 29
Clinical Pharmacology and Therapeuticsof Antidepressants
Ciraulo, D. A., Shader, R. I., & Greenblatt, D. J. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-435-7_2 · Cited by 25
Johnson, C. F. A., Dougall, N. J., Williams, B., MacGillivray, S. A., Buchanan, A. I., & Hassett, R. (2014) · BMC Family Practice · doi:10.1186/s12875-014-0210-9 · Cited by 25
Potential Sensitising Effects of Antidepressant Drugs on Depression
Fava, G. A. (1999) · CNS Drugs · doi:10.2165/00023210-199912040-00001 · Cited by 23
Tachyphylaxis/ tolerance to antidepressive medications: a review.
Katz, G. (2011) · PubMed · Cited by 23
Residual symptoms in depression
Sonino, N., & Fava, G. A. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(02)00200-2 · Cited by 23
Failure to Respond after Reinstatement of Antidepressant Medication: A Systematic Review
Bosman, R. C., Waumans, R. C., Jacobs, G. E., Oude Voshaar, R. C., Muntingh, A. D. T., Batelaan, N. M., & van Balkom, A. J. L. M. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000491550 · Cited by 21
Selective Serotonin Reuptake Inhibitors: How Long Is Long Enough?
Thom, R. P., Alexander, J. L., Baron, D. A., Garakani, A., Gross, L. S., Pine, J. H., Radhakrishnan, R., Slaby, A. E., & Sumner, C. R. (2021) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000578 · Cited by 21
Clinical Pharmacology and Therapeutics of Antidepressants
Ciraulo, D. A., Tsirulnik-Barts, L., Shader, R. I., & Greenblatt, D. J. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-792-5_2 · Cited by 21
Impact of Study Design on the Results of Continuation Studies of Antidepressants
Zimmerman, M., Posternak, M. A., & Ruggero, C. J. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31803308e1 · Cited by 20
Withdrawing patients from antidepressants
(1999) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.1999.37749 · Cited by 19
Wainwright, S. R., Barha, C. K., Hamson, D. K., Epp, J. R., Chow, C., Lieblich, S. E., Rutishauser, U. S., & Galea, L. A. M. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.337 · Cited by 20
Chasing the Latest Fad: Confronting Recent and Historical Innovations in Mental Illness
Overholser, J. C. (2013) · Journal of Contemporary Psychotherapy · doi:10.1007/s10879-013-9250-z · Cited by 20
Psicoterapias comportamentais no tratamento da depressão
Cardoso, L. R. D. (2017) · Psicologia Argumento · doi:10.7213/psicolargum.v29i67.20359 · Cited by 19
Zhang, M., Zhou, D., Wang, Y., Maier, D. L., Widzowski, D., Sobotka‐Briner, C. D., Brockel, B. J., Potts, W. M., Shenvi, A. B., Bernstein, P. R., et al. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.174433 · Cited by 19
Tolerance to antidepressant treatment may be overcome by ketoconazole. Report of two cases
Sonino, N., & Fava, G. A. (2003) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(02)00089-4 · Cited by 19
Organic Cation Transporters in Psychiatric Disorders
Daws, L. C. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_473 · Cited by 18
Weinberger, A. H., Hitsman, B. L., Papandonatos, G. D., Sacco, K. A., Vessicchio, J. C., & George, T. P. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181bfd0b4 · Cited by 18
A systematic review and meta-analysis of trials of treatment of depression from India
Grover, S., & Sarkar, S. (2014) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.124711 · Cited by 17
The Rothschild scale for antidepressant tachyphylaxis: reliability and validity
Rothschild, A. J. (2008) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2008.03.002 · Cited by 15
“However, the presentation of antidepressant tachyphylaxis or “poop-out” is often distinct from that of an initial or recurrent major depressive episode [8].”
BackgroundSelf-citationCan long-term antidepressant use be depressogenic?
El-Mallakh, R. S., Waltrip, C., & Peters, C. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0412e · Cited by 14
Devi, M. N., & Sharma, R. (2014) · International journal of Nutrition Pharmacology Neurological Diseases · doi:10.4103/2231-0738.129603 · Cited by 14
Antidepressant-Induced Tardive Dysphoria
El-Mallakh, R. S., Gao, Y., Briscoe, B. T., & Roberts, R. J. (2011) · Psychotherapy and Psychosomatics · doi:10.1159/000316799 · Cited by 13
Xiao, C., Zhou, J. L., Li, A., Zhang, L., Zhu, X., Zhou, J., Hu, Y., Zheng, Y., Liu, J., Deng, Q., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.28817 · Cited by 14
The economic burden associated with SSRI treatment failure in a managed care population
Balkrishnan, R., Joish, V. N., Yang, T. T., Jayawant, S. S., & Mullins, C. D. (2008) · Journal of Medical Economics · doi:10.3111/13696990802522339 · Cited by 13
In vivo Effect of Antidepressants on [3H]paroxetine Binding to Serotonin Transporters in Rat Brain
Nadgir, S. M., & Malviya, M. (2008) · Neurochemical Research · doi:10.1007/s11064-008-9703-z · Cited by 13
Paroxetine mesylate: comparable to paroxetine hydrochloride?
Pae, C., Misra, A., Ham, B., Han, C., Patkar, A. A., & Masand, P. S. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903451708 · Cited by 12
Katz, G. (2011) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2011.02231.x · Cited by 12
Tokunaga, N., Takimoto, T., Nakamura, Y., Hisaoka‐Nakashima, K., & Morioka, N. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174986 · Cited by 11
Coplan, J. D., Singh, D., Gopinath, S., Mathew, S. J., & Bulbena, A. (2015) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.14060132 · Cited by 11
The meaning of depression: Swedish nurses’ perceptions of depressed inpatients
Lilja, L., Hellzén, M., Lind, I., & Hellzèn, O. (2006) · Journal of Psychiatric and Mental Health Nursing · doi:10.1111/j.1365-2850.2006.00946.x · Cited by 12
Andrews, P. W., & Amsterdam, J. D. (2020) · Psychiatria Polska · doi:10.12740/pp/120084 · Cited by 11
Delayed Loss of Efficacy and Depressogenic Action of Antidepressants
Raja, M. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181c0e60b · Cited by 10
Sequential treatment of depression in primary care
Rafanelli, C., Fava, G. A., & Sonino, N. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01342.x · Cited by 10
Fluoxetine treatment for major depression decreases the plasma levels of cytokines
Shen, Y., Lu, P., Wei, L., Cai, L., Hu, X., & Chen, W. (2010) · AFRICAN JOURNAL OF BIOTECHNOLOGY · doi:10.5897/ajb10.1097 · Cited by 7
Agitated dysphoria after late-onset loss of response to antidepressants: A case report
Phelps, J. R. (2005) · Journal of Affective Disorders · doi:10.1016/j.jad.2005.02.005 · Cited by 9
Well-being Therapy in Depressive Disorders
Mansueto, G., & Cosci, F. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-33-6044-0_19 · Cited by 8
Metadata
- Authors
- Byrne, S. E., & Rothschild, A. J.
- Affiliations
- Cambridge Hospital (US)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 1998-06-15
- Volume
- 59
- Issue
- 6
- Pages
- 279-288
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2083405172
- Cited by
- 149
- References
- 0
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 3 · 2023: 2 · 2022: 4 · 2021: 5 · 2020: 3 · 2019: 1 · 2018: 7 · 2017: 3 · 2016: 2 · 2015: 9 · 2014: 7 · 2013: 3 · 2012: 6
- FWCI
- 3.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- eScholarship@UMassChan (submittedVersion)
- Funders
- National Institutes of Health (7r29mh047457-06)
- National Institute of Mental Health (MH-47457)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
- Keywords
- antidepressant efficacy, maintenance therapy, relapse, major depressive disorder, placebo effect, rapid cycling, antidepressant metabolites, prophylaxis, disease severity
- MeSH terms
- Adult, Aged, Antidepressive Agents, Antidepressive Agents, Tricyclic, Clinical Trials as Topic, Depressive Disorder, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Drug Tolerance, Female, Humans, Male, Middle Aged, Monoamine Oxidase Inhibitors, Research Design, Severity of Illness Index, United States, Placebo Effect, MEDLINE, Selective Serotonin Reuptake Inhibitors, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.